195 related articles for article (PubMed ID: 31088714)
1. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
[TBL] [Abstract][Full Text] [Related]
2. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
[TBL] [Abstract][Full Text] [Related]
3. Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.
Lee J; Kim AH; Yi S; Lee S; Yoon SH; Yu KS; Jang IJ; Cho JY
AAPS J; 2017 Jul; 19(4):1196-1204. PubMed ID: 28523515
[TBL] [Abstract][Full Text] [Related]
4. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
[TBL] [Abstract][Full Text] [Related]
5. Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects.
Lee S; Lee Y; Kim AH; Yoon S; Lee J; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2021 Feb; 36():100374. PubMed ID: 33348239
[TBL] [Abstract][Full Text] [Related]
6. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.
Shin KH; Choi MH; Lim KS; Yu KS; Jang IJ; Cho JY
Clin Pharmacol Ther; 2013 Nov; 94(5):601-9. PubMed ID: 23784264
[TBL] [Abstract][Full Text] [Related]
8. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
9. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
[TBL] [Abstract][Full Text] [Related]
10. The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects.
Lee S; Kim AH; Yoon S; Lee J; Lee Y; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2021 Feb; 36():100368. PubMed ID: 33348240
[TBL] [Abstract][Full Text] [Related]
11. Stimulatory and Inhibitory Effects of Steroid Hormones and Human Cytochrome P450 (CYP) 3A Inhibitors on Cortisol 6β-Hydroxylation Catalyzed by CYP3A Subfamilies.
Niwa T; Tani M; Suzuki A; Murakami M
Drug Metab Bioanal Lett; 2023; 16(2):73-80. PubMed ID: 37649294
[TBL] [Abstract][Full Text] [Related]
12. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Tahara H; Watanabe M; Hasegawa M
Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
[TBL] [Abstract][Full Text] [Related]
13. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD
Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
[TBL] [Abstract][Full Text] [Related]
15. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
16. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
[TBL] [Abstract][Full Text] [Related]
17. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment.
Kim AH; Yoon S; Lee Y; Lee J; Bae E; Lee H; Kim DK; Lee S; Yu KS; Jang IJ; Cho JY
J Korean Med Sci; 2018 Dec; 33(53):e298. PubMed ID: 30595680
[TBL] [Abstract][Full Text] [Related]
19. UHPLC-MS/MS bioanalysis of urinary DHEA, cortisone and their hydroxylated metabolites as potential biomarkers for CYP3A-mediated drug-drug interactions.
Zheng N; Christopher LJ; Ma X; Ji QC; Buzescu A; Kandoussi H; Garonzik SM; LaCreta F; Aubry AF; Arnold ME; Zeng J
Bioanalysis; 2016 Dec; 8(23):2429-2443. PubMed ID: 27855510
[TBL] [Abstract][Full Text] [Related]
20. Effect of breviscapine on CYP3A metabolic activity in healthy volunteers.
Zhou X; Gao YY; Hu JY; Dong Y; Zhang HZ; Lai Y
Eur J Clin Pharmacol; 2018 Jan; 74(1):37-44. PubMed ID: 28986606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
